Recombinant Human IL-15 Protein, Active, Low Endotoxin
Description
Product Overview
| Product Name | Recombinant Human IL-15 Protein |
| Target Symbol | IL15 |
| Alternative Names | Interleukin 15, IL15, MGC9721 |
| Accession Number | P40933 |
| Expression System | E.Coli. |
| Molecular Weight | 12.9 kDa (predicted, monomer) |
| Sequence | Asn49-Ser162, with an N-terminal Met |
| Purity | >95% by SDS-PAGE and quantitative densitometry by Coomassie® Blue staining. |
| Activity | Determined by a cell proliferation assay using mouse CTLL-2 cells. The ED50 for this effect is typically <0.5 ng/mL. |
| Formulation | Lyophilized from sterile PBS with Trehalose, pH 7.4 |
| Endotoxin Level | <0.05 EU/1ug of the protein as determined by the LAL method. |
| Shipping | Shipped at ambient temperature. |
| Stability & Storage | 12 months from date of receipt at -20°C to -70°C, lyophilized powder. 3 months at -20°C to -70°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw cycles. |
| Reconstitution | Reconstitute at 100 ug/mL in sterile PBS. |
| Target Function | IL-15 is a cytokine closely related to IL-2 in that it stimulates CD4+ Th cells, CD8+ Tc cells and NK cells. Notably, IL-15 is not associated with a strong Treg response and uses a variation in receptor signaling to distinguish its mechanism from IL-2. IL-15 predominately uses a cell-to-cell juxtacrine interaction involving an IL-15 responsive cell expressing the IL-2 R beta (CD122)/common gamma chain (CD132) complex and, in a process termed transpresentation, IL-15 bound to IL-15 R alpha (CD215) on the surface of second, effector cell completes the signaling interaction. In a less regulated fashion, free IL-15 is able to induce signaling through the IL-2 R beta (CD122)/common gamma chain (CD132) complex. Through these interactions IL-15 is also associated with an exercise-induced skeletal response and interstitial adipose metabolism. IL-15 is being investigated for its potential to improve the efficacy of adoptive cell therapies (ACT), such as CAR-T cell therapy and TCR-engineered T cell therapy. IL-15 is being investigated in combination with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1 antibodies) and other cytokines (e.g., IL-2), to enhance anti-tumor immune responses. |
| Tissue Specificity | IL-15 expression has been reported in bone marrow stromal cells, muscle tissue, epithelial cells, and adipose tissue |
| Cellular Localization | Cell surface and secreted protein forms |
| Involvement In Disease | Dysregulation of IL-15 has been implicated in inflammatory disorders like allergic asthma, chronic obstructive pulmonary disease (COPD) and psoriasis; autoimmune disorders such as rheumatoid arthritis and multiple sclerosis; metabolic disorders such as obesity, insulin resistance; cancer tumor metastasis and immune evasion. |
Intended use
Research Use Only
Specifications
| Product information | |
|---|---|
| Catalog number | BEP-0014 |
| Size | 100ug |
Need a different construct, tag or scale?
Our custom recombinant protein production service covers gene synthesis, expression in E. coli, yeast, insect and mammalian cells, purification and QC, for Non-GMP research or GMP manufacturing.